Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ABO1009-DP (Omicron) mRNA Vaccine Booster
NCT05433194Phase 1Unknown
- Sponsor
- Abogen Bioscience
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABO1009-DP in coronavirus disease 2019 (COVID-19), sponsored by Abogen Bioscience. Primary endpoints: Incidence of solicited adverse events, Incidence of unsolicited adverse events and 1 more. Status: unknown.
02
Drugs
ABO1009-DP
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05433194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433194.